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Psoriasis is a chronic, relapsing skin disease that may require multiple treatment 
courses. Alefacept targets the memory T cells implicated in psoriasis pathogenesis. This open-
label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat 
courses of alefacept in men and women with chronic plaque psoriasis. This article reports the 








 = 174) who participated in previous phase II studies of alefacept were 
included in this retreatment study. Intravenous alefacept (7.5 mg) was administered once 
weekly for 12 weeks followed by 12 weeks of observation. Initial and subsequent retreatment 









Adverse events were similar regardless of the retreatment course. No opportunistic 
infections, rebound of disease, or flares were reported. Low titers of anti-alefacept antibodies 





 50% reduction in the Psoriasis Area and Severity Index (PASI) at any time after the first dose 




 = 50) had consistent 




 50% PASI improvement at any time after the first dose of retreatment courses 1 and 2, 




Repeat courses of alefacept were well tolerated, and subsequent retreatment 
courses were at least as effective as the initial course of therapy.
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Psoriasis is a chronic, relapsing skin disease that affects
approximately 5.1 million individuals in Europe and more




 The National Psoriasis Founda-
tion estimates that between $1.6 and $3.2 billion is spent each
year in the USA on psoriasis treatments alone, and that the




This significant economic burden is accompanied by reduc-




 Individuals with psoriasis fre-
quently experience physical symptoms (e.g. scaling, itching,
skin redness), psychosocial problems (e.g. interacting with
peers and family), and difficulty performing routine activities
(e.g. exercising, sleeping, sexual activities). Nearly 80% of





Psoriasis is now recognized as an immune-mediated disease









 Alefacept is a novel and selective biologic agent that
targets this T-cell subset. It is a fully human fusion protein
consisting of the first extracellular domain of lymphocyte













. LFA-3 is a cell surface recep-
tor found on immune accessory cells (e.g. natural killer cells,
macrophages). The LFA-3 portion of alefacept binds to the
CD2 receptor on T cells, thereby blocking their natural
interaction with LFA-3 on antigen-presenting cells and thus





















 alefacept produces a selective




As previously reported, a single course of intravenous ale-
facept was well tolerated and significantly improved psoria-




Because of the long-lasting, relapsing nature of psoriasis, it is
important to study the effects of repeat courses of alefacept.




















safety and tolerability of repeat courses of intravenous ale-
facept in men and women with chronic plaque psoriasis who
participated in previous phase II studies of alefacept. Efficacy
and pharmacodynamic effects were secondary objectives.






Men and women with chronic plaque psoriasis who participated in 
previous phase II studies of alefacept were eligible for this 
retreatment study. Patients were eligible for the phase II studies if 




 10% of the body 
surface area which was diagnosed at least 12 months before study 
entry, were receiving systemic treatment or phototherapy or were 
candidates for such treatment, and had no serious hepatic or renal 
disease, history of cancer (basal cell carcinoma or less than three 
squamous cell carcinomas of the skin were permitted), or serious 
infection within the previous 3 months. Patients had to complete 
the 12-week treatment and observation phases of the phase II 
studies before being considered for the retreatment study.
Patients were not eligible for retreatment courses until their 
disease had returned to a level at which the investigator judged 
that systemic therapy or phototherapy was required. Alefacept 




 T-cell counts were at 
or above the lower limit of normal. The retreatment study was 
conducted in accordance with the Declaration of Helsinki, and all 
patients provided written informed consent before enrolment. The 





In the previous phase II studies, patients received one or two 
courses of alefacept or one course of placebo. A treatment course 
was defined as 12 weeks of once-weekly treatment followed by 
12 weeks of observation. A wide range of doses were studied: 
0.025–0.75 mg/kg intravenously, 0.15–0.375 mg/kg 
intramuscularly, and 0.15–0.75 mg/kg subcutaneously.
In the ongoing, open-label, multicenter (18 US centers) 
retreatment study, eligible patients received alefacept (7.5 mg) 
once weekly as a 30-s intravenous bolus for a treatment period of 
12 weeks. A minimum 12-week washout period was required after 
each treatment course; thereafter, patients could be considered for 
a subsequent retreatment course if needed. In the retreatment 


















L. Dosing was withheld 
for 2 weeks when fever or evidence of clinically significant infection 









L on four consecutive visits.
Patients returned to the clinic for safety, tolerability, efficacy, and 
pharmacodynamic evaluations weekly during each treatment 
phase, at 2, 4, 6, 8, and 12 weeks during the follow-up phase of the 
first retreatment course, and at 2, 6, and 12 weeks during the 
follow-up phases of subsequent retreatment courses. Whenever 





Before receiving the initial and subsequent retreatment courses, 
patients observed a 2-week washout period from treatment with 
moderate-potency topical corticosteroids, vitamin D analogs, 
topical retinoids, keratolytics, and coal tar (other than on the groin, 
scalp, palms, and soles). Moreover, a 4-week washout period from 
treatment with other investigational agents, systemic psoriasis 
therapies, high-potency topical corticosteroids, and phototherapy 
was required.
Moderate-potency topical corticosteroids, vitamin D analogs, 
topical retinoids, keratolytics, and coal tar could be used 
throughout the retreatment study on the groin, scalp, palms, and 
soles only. Low-potency topical corticosteroid use was permitted, 
if necessary, but not within 12 h of efficacy evaluations. Patients 
were not permitted to receive systemic psoriasis therapies, 
high-potency topical corticosteroids, or phototherapy at any time 
during the retreatment study.
 
Safety and tolerability assessments
 
All adverse events reported by the patient or observed by study 
personnel were recorded throughout the retreatment study. 
Medical histories, physical examinations, vital signs, blood 
chemistries (sodium, potassium, chloride, bicarbonate, blood urea 
nitrogen, creatinine, calcium, phosphate, albumin, total protein, 
alkaline phosphatase, total bilirubin, alanine aminotransferase, 
aspartate aminotransferase, and gamma glutamyl transaminase), 
complete blood counts (with differential and platelet count), and 
urinalyses were performed at various times throughout the 
retreatment study. Patients were also monitored for the possible 
development of anti-alefacept antibodies through the collection of 
whole blood at baseline (retreatment course 1 only) and at 6 and 
12 weeks during the follow-up phase of each retreatment course. 
Anti-alefacept antibody analyses were performed at Biogen, Inc. 
(Cambridge, MA, USA). All other laboratory tests were performed 





The Psoriasis Area and Severity Index (PASI) and Physician 
Global Assessment (PGA) were used to measure disease severity. 
PASI scores, which range from 0 (no psoriasis) to 72 (the most 
severe disease possible), combine assessments of the extent of 





 For PGA, a seven-point scale 
rating disease severity as “clear”, “almost clear”, “mild”, “mild to 
moderate”, “moderate”, “moderate to severe”, or “severe” was 
used. In retreatment course 1, PASI and PGA evaluations were 
performed before treatment, at 3, 5, 7, 9, 11, and 12 weeks during 
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treatment, and at all follow-up visits. In subsequent retreatment 
courses, these evaluations were performed before treatment, at 
7 weeks during treatment, and at 2 and 12 weeks during follow-up.
In each retreatment course, efficacy endpoints included the 




 75% PASI reduction from 




 50% PASI reduction from baseline, and PGA of “clear” or “almost 
clear” at 2 weeks after treatment cessation (primary endpoint). 





 efficacy endpoints were also measured at any 



































 B cells were determined from blood samples obtained at all 
study visits (except at 4 weeks after treatment cessation in retreat-





Disposition and baseline characteristics
 









 = 30) in previous
phase II studies. Of these patients, 174, 107, and 23 have thus
far received at least one dose of alefacept during retreatment
courses 1, 2, and 3, respectively. All patients were included in
the safety analyses. The majority of patients in each course
received all 12 doses of study drug (67% and 62% for retreat-
ment courses 1 and 2, respectively); no patient has completed
retreatment course 3 to date. Only two patients permanently




 T-cell counts (see “Safety
and tolerability” section). Only patients who completed the
12-week follow-up phase of a course or withdrew from the
study were included in the efficacy and pharmacodynamic
analyses; at this time, 170 patients are evaluable in retreat-
ment course 1, and 50 patients are evaluable in retreatment
courses 1 and 2.
The mean age of the patients enrolled in this study was
45 years; 66% were male, and 84% were white. Patients
had a mean weight of 95 kg and a mean height of 173 cm. At
baseline, the median body surface area involvement of
psoriasis ranged from 19% to 21% in the three retreatment
courses, and the median PASI score ranged from 9.9 to 13.3.
The baseline PGA was “moderate” or “moderate to severe”
in 78%, 61%, and 57% of patients during retreatment




Repeat courses of alefacept were similarly well tolerated. The
most common adverse events were pharyngitis (13%) and
rhinitis (13%) in retreatment course 1, and infection (7%)
and pharyngitis (7%) in retreatment course 2 (Table 1). The
common cold was the most frequent event coded to “infec-
tion”. There were no complicated or opportunistic infections.
Rebound of disease or flare did not occur after completion of
either retreatment course 1 or 2. No serious, drug-related
adverse events were reported throughout the study.
Discontinuation rates because of adverse events were
low (< 2%) in retreatment courses 1 and 2. Adverse events
resulted in the discontinuation of three patients from retreat-




 T-cell counts, one for pneu-
monia) and two patients from retreatment course 2 (one for
herpes zoster, one for pulmonary fibrosis). The herpes zoster
and pneumonia resolved with conventional treatment. The





counts, one patient was withdrawn after receiving two doses
of alefacept (7.5 mg) and one dose of alefacept (3.75 mg); the
Adverse event
Retreatment course 1 Retreatment course 2 Retreatment course 3 
n (%) n (%) n (%)
Pharyngitis 23 (13) 8 (7) 0
Rhinitis 22 (13) 7 (7) 0
Accidental injury 19 (11) 6 (6) 0
Viral infection 18 (10) 7 (7) 2 (9)
Flu syndrome 15 (9) 3 (3) 0
Headache 15 (9) 5 (5) 0
Pain 13 (7) 7 (7) 1 (4)
Infection 9 (5) 8 (7) 0
Nausea 9 (5) 2 (2) 0
Pruritus 8 (5) 1 (< 1) 0
Sinusitis 6 (3) 6 (6) 0
Total number of patients completing retreatment courses 1, 2, and 3 are 174, 107, and 
23, respectively.
Table 1 Adverse events reported in ≥ 5% 





















































reported at the last available follow-up visit. The other patient




 T-cell counts had a normal count









associated with each of the first four alefacept injections,








L at the last available follow-up




 T-cell counts, there were no
accompanying adverse events of note.
Five patients had malignancies diagnosed during the study.
One 65-year-old woman with a family history of colon cancer
and a recent medical history of guaiac-positive stools was
diagnosed with adenocarcinoma of the colon. A 66-year-old
man with a history of heavy smoking was diagnosed with ade-
nocarcinoma of the lung. Three patients with long-standing
psoriasis (19–34 years) and previous exposure to psoralen
plus ultraviolet A (PUVA) and methotrexate were diagnosed
with squamous cell carcinoma of the skin. All five patients
received appropriate surgery and treatment.
There were no clinically important trends in medical his-
tory or physical examination findings, vital signs, or standard
laboratory test results. Of the 174 patients dosed in retreat-
ment course 1, three (1.7%) tested positive for anti-alefacept
antibodies after treatment initiation, one of whom tested pos-
itive before dosing. Two patients tested positive before dosing
in retreatment course 1, but did not have a positive result after
the start of therapy. Of the 107 patients dosed in retreatment
course 2, one (< 1%) tested positive after beginning therapy.





In the previous phase II studies, alefacept significantly im-
proved psoriasis symptoms. Alefacept had a consistent efficacy
profile during repeat courses. Maximum mean reductions
from baseline PASI were 51% at 6 weeks after the last dose
of retreatment course 1, and 47% at 2 weeks after the last
dose of retreatment course 2 (Fig. 1). Retreatment course 2
baseline was lower relative to the baseline of retreatment
course 1 (by approximately 30%), suggesting that patients
who entered the second retreatment course of therapy had
retained some clinical improvement from the first retreatment
course. In retreatment course 1, overall response rates for








 50% PASI reduction were
29%, 39%, and 66%, respectively (Fig. 2a). Of the 50
patients who received two consecutive retreatment courses of
alefacept, the percentage of patients who responded during
the second course was consistent with or better than that
Figure 1 Mean percentage reductions from the baseline 
Psoriasis Area and Severity Index during repeat courses of 
intravenous alefacept. The arrow indicates 2 weeks after the last 
dose of treatment, the primary endpoint
Figure 2 Physician Global Assessment (PGA) of “clear” or 
“almost clear” and reductions in the Psoriasis Area and Severity 
Index (PASI) of ≥ 50% and ≥ 75% in patients retreated with 
intravenous alefacept during retreatment course 1 (a) and in 
patients who received two retreatment courses (b). The bars 
indicate the percentage of patients who achieved various degrees 
of improvement. In (b), only the 50 patients who completed both 
retreatment courses are included. The primary study endpoint 
was 2 weeks after the last dose and the overall response rate was 
defined as the response any time after the first dose of study drug
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observed during the first course (Fig. 2b). In both retreatment
courses, patients continued to improve after the dosing interval.




 75% decrease in PASI at
12 weeks post-dosing than at any time during the dosing interval




Alefacept reduced total lymphocyte and lymphocyte subset
counts to a similar extent over both retreatment courses.








 naive T cells over retreatment
























43% relative to retreatment course 1 baseline) in retreat-








41% relative to retreatment
course 1 baseline) in retreatment course 2. Correspond-


































 B cells through-
out the study. Ninety-eight per cent of patients had total
lymphocyte counts at or above the lower limit of normal at 12
weeks after the last dose, regardless of retreatment course;




 T-cell counts at or above
the lower limit of normal at 12 weeks after the last dose




Psoriasis is a chronic disease with, as yet, no cure. Treatments
are available to reduce or suppress the symptoms, but do not
provide long-lasting disease remission. Currently available
agents for psoriasis are generally efficacious, but safety,
tolerability, and the need for regular laboratory or other
evaluations are often a concern. Cyclosporine is nephrotoxic,
particularly with long-term use,13 while methotrexate is asso-
ciated with bone marrow toxicity during short-term use and
hepatotoxicity during extended use.14 Both of these agents
can also interact with a variety of drugs, thereby increasing
the potential for toxicity.15 Retinoids are teratogenic, invaria-
bly produce mucocutaneous side-effects, and are less effica-
cious than cyclosporine or methotrexate.16 PUVA use is
associated with a dose-related increase in the risk of squa-
mous cell carcinoma17 and possibly melanoma.18 These data
underscore the need for safer and better tolerated, longer term
psoriasis therapies, thus benefiting a patient’s quality of life.
Alefacept was well tolerated when used in repeat 12-week
courses for the treatment of chronic plaque psoriasis. The
most common adverse events in this retreatment study were
pharyngitis, rhinitis, and infection, which was most com-
monly associated with a cold. No opportunistic infections,
rebound of disease, or flares were reported. The patient in
whom lung fibrosis was diagnosed had a 24-year history of
coal dust exposure and a history of pneumonia, both of which
were thought to have contributed to the fibrosis. The patient
also had a significant smoking history. Five cases of malig-
nancy (two systemic, three skin) were reported in the study; in
each case, there were additional risk factors that probably
contributed to the occurrence. In addition, the incidence of
these cancers is similar to that expected in untreated individ-
uals of the same age. A total of 22 patients of at least 60 years
of age were enrolled in this study, and the incidences of colon
and lung cancer in this age group are approximately 1 in 25
and 1 in 16, respectively.19
Consistent with its fully human protein composition, the
immunogenicity of alefacept was very low.
Figure 3 Percentage of patients who achieved a ≥ 75% reduction 
from baseline in the Psoriasis Area and Severity Index (PASI) 
during repeat courses of intravenous alefacept. The arrow 
indicates 2 weeks after the last dose of treatment, the primary 
endpoint
Figure 4 Mean changes in memory (CD4+CD45RO+) and naive 
(CD4+CD45RA+) T-cell counts during repeat courses of 
intravenous alefacept. Results are shown for the 50 patients who 
received two retreatment courses of alefacept. The arrow 
indicates 2 weeks after the last dose of treatment, the primary 
endpoint
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Although this was an open-label study, the efficacy results
of the first retreatment course, with overall response rates of
39% for patients achieving a ≥ 75% reduction in PASI from
baseline and 66% with a ≥ 50% reduction, are consistent
with those of a previous randomized, placebo-controlled,
double-blind study.11 The overall response rates as defined
in this study are likely to be more important to patients and
physicians in clinical practice compared with response rates
measured at a single time point. Alefacept provided con-
sistent clinical benefit following one or more retreatment
courses. Patients had either an equivalent clinical response
or further improvement after a second retreatment course.
Efficacy increased over time in both retreatment courses.
There was no evidence of tachyphylaxis.
Patients entering the second retreatment course had a lower
disease burden relative to those entering the first retreatment
course, as suggested by the 30% lower mean baseline PASI
score, indicating a sustained treatment benefit. The results
support those of a previous study suggesting that alefacept is
a remittive rather than suppressive therapy.11 Remittive ther-
apies have the advantage of increasing the time a patient is off
medication and allowing for more disease-free living. PUVA
and Goeckerman therapy are the only remittive therapies
currently available;20–22 however, as mentioned previously,
PUVA is associated with safety concerns, especially with long-
term use; in addition, Goeckerman therapy is extremely time
intensive for both the patient and physician and may require
three or more weeks of daily, day-long sessions to induce
remission.22
As seen in other clinical studies,11 alefacept selectively
reduced memory T cells, with relative sparing of naive T cells.
The mechanistic basis for this specificity involves at least
two factors: the level of CD2 expression and the rate of
replenishment of the different subpopulations. Memory T
cells have higher CD2 expression relative to naive T cells.9, 10
Both memory and naive T cells can regenerate, but the
absolute rate of replenishment (> 108−109 cells/day) is
greater for naive T cells because of daily production by the
thymus.23 Over the multiple retreatment courses, a cumula-
tive effect on lymphocytes or lymphocyte subsets was not
observed. Nadirs and rates of recovery were similar with
repeat dosing. A correlation between the extent of reduction
in memory T cells and clinical response has previously been
demonstrated,11 supporting the belief that this T-cell popula-
tion contains the clonal precursors that drive psoriasis disease
activity.6, 24
Maintaining excellent safety, tolerability, and efficacy over
multiple courses of treatment is important because of the
chronic and relapsing nature of psoriasis. Intravenous ale-
facept was well tolerated and had a consistent safety and tol-
erability profile during repeat courses. The clinical response
to alefacept was consistent amongst patients who received
two retreatment courses, with a trend for additional benefit in
retreatment course 2. Repeat courses of alefacept selectively
reduced memory T cells without cumulative effects.
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